Physician profile
Robert Blake Lowe
NPI 1326400854
$989.78
in general payments reported to CMS, 2019-2025
18 companies · $696 in 2025
The $696 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $294 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $231.96 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $173.42 | 2024-2025 | |
| Novo Nordisk INC | $152.30 | 2024-2025 | Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $79.92 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $57.35 | 2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.57 | 2025 | Caplyta |
| Djo, LLC | $41.43 | 2024 | Cmf |
| Phathom Pharmaceuticals, INC. | $32.70 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.69 | 2025 | Xifaxan |
| Exact Sciences Corporation | $20.28 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $19.53 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $18.17 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $17.85 | 2025 | Airsupra |
| Lilly USA, LLC | $17.42 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.80 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $15.28 | 2024 | Strensiq |
| Collegium Pharmaceutical, INC. | $14.06 | 2025 | Jornay Pm |
| Astellas Pharma US INC | $14.05 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.